♥ HF Guideline NavigatorESC 2026

7 › 7.4 › 7.4.2

7.4.2 Phase 2 (stabilization)

Pages 45–46 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 45 · PDF

                             

                            

          

                     ­   €                                                  

Figure 12 Phases and goals for in-hospital management of decompensated heart failure. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure. aSee Figure 14.

7.4.1. Phase 1 (initial management) The primary objectives in phase 1 are reported in Figure 12. In many cases, this phase starts in pre-hospital settings. Pre-hospital management should not delay the rapid transfer of the patient to the most appropriate medical setting, where further work-up is undertaken. Patients should be triaged based on their haemodynamic and clinical status to determine the appropriate level of care and monitoring requirements. For patient risk stratification, specific scores have been proposed, but they need further validation (see Supplementary data online, Section S4.2.1).486,487 In patients with suspicion of CS and with a potential indication for temporary MCS, consultation with the Shock Team is recommended (see Section 7.5.11).488 In these patients, as well as in those with other life-threatening conditions, the diagnostic

work-up and appropriate rescue pharmacological and nonpharmacological treatment should be initiated promptly and simultaneously (Figure 13). Identification and possible treatment of acute causes is crucial.118,119,489–491 Combination and timing of different treatments depend on clinical presentation (Figure 13). In patients already receiving FMT, continuation and/or rapid reintroduction as soon as possible is recommended. Discontinuation of FMT is not recommended unless there are clear signs of hypoperfusion or specific clinical indications. Monitoring during and after initial stabilization is mandatory (see Supplementary data online, Table S12).

7.4.2. Phase 2 (stabilization) The primary objective of this phase is to maintain and enhance the patient’s haemodynamic status and, once the patient is

Page 46 · PDF

tween different clinical phenotypes can exist. bConsultation with the Shock Team is recommended. cConsider in case of hypoxaemia. Consider when systolic blood pressure is >110 mmHg.

stabilized, to start/optimize long-term FMT to alter the course of the disease and improve patient outcomes. Decongestion is crucial and must be started and continued in phase 2 (Figure 13). Data from recent RCTs have demonstrated that initiating MRAs, SGLT2-Is, or ARNIs is feasible and safe in this phase of DHF.281,492,493 Much debate is ongoing on the optimal FMT initiation/optimization. It is clear that the traditional sequential approach is suboptimal and time-consuming. There is growing evidence that simultaneous implementation of FMT is more effective, safe, and associated with clinical benefit, thus this approach should be preferred. As no prospective RCT has been conducted comparing the different approaches to implementing FMT, no specific recommendation can be made regarding the number of drug classes to be introduced simultaneously or sequencing of the drugs. A more conservative approach may be reserved for specific (high-risk) groups of patients, such as patients with low eGFR, hypotension, and history of hyperkalaemia.

7.4.3. Phase 3 (pre-discharge and early post-discharge) This transition phase covers the last days of hospitalization and the first days/weeks after discharge.494 During this period, efforts should focus on reducing the risk of subsequent DHF/WHF

episodes, further optimizing FMT, and determining any indications for AMT and GDIT. The STRONG-HF trial demonstrated the safety and efficacy of an approach based on a rapid and intensive initiation and uptitration of FMT followed by close outpatient visits.311 This study has been criticized due to several limitations, including a highly selected population (based on NT-proBNP values and changes), the suboptimal medical treatment in the control arm and the lack of SGLT2-I use (lack of evidence and recommendations at the time when the study was conducted). Nevertheless, the trial showed that a strategy of fast uptitration after HFH is safe and feasible and therefore this approach is recommended. Safety indicators, including vital signs (blood pressure and heart rate) and laboratory tests (creatinine, potassium, and NT-proBNP) are helpful to guide uptitration.495 Residual congestion is associated with poor outcomes and a high risk of rehospitalization. Thus, pre-discharge assessment of residual congestion using clinical, laboratory, and imaging techniques is recommended (Figure 14).494 If not done earlier, the predischarge phase may also be used for iron supplementation in patients with iron deficiency (ID), based on the results of the AFFIRM-AHF trial (see Section 10.4).496 Finally, patients should be enrolled in disease management and rehabilitation programmes, educated, and guided in appropriate lifestyle adjustments.

Figure 13 Initial management of decompensated heart failure. HF, heart failure; MCS, mechanical circulatory support. aOverlap be-